Back to results
US 9,970,943 B2Granted
Mass spectrometric assays for peptides
AssigneeAnderson Forschung Group, Inc.
InventorN. Leigh Anderson
Life of this patent
Estimating the term…
Abstract
Methods for interpretation of mass spectrometric tests for clinical biomarkers in which the amounts of internal standards are set to equal clinical evaluation thresholds, and preparations for adding stable isotope labeled peptide species to sample digests while minimizing losses and alterations in peptide stoichiometry.
Claims5
A method of standardizing a quantitative mass spectrometric assay for a peptide analyte in a sample, comprising:
- adding a known amount of a SIS version of said analyte to a known amount of said sample, to form a standardized sample,
- measuring by mass spectrometry the relative amounts of said peptide analyte and said SIS version of said analyte in said standardized sample, and
- comparing the amount of said peptide analyte to the amount of said SIS version of said analyte, wherein said known amount of said SIS version of said analyte corresponds to the analyte amount at a pre-determined test evaluation threshold, wherein said test evaluation threshold is a clinical decision threshold derived from a clinical study establishing test sensitivity and specificity at said threshold.
A method of standardizing a mass spectrometric assay for a protein or peptide analyte in a sample comprising:
- adding known amounts of a first SIS version of said analyte and a second SIS version of said analyte as internal standards to a known amount of said sample prior to mass spectrometric analysis;
- wherein said known amount of said first SIS version corresponds to the analyte amount at the lower end of the established clinical reference range for the analyte and said known amount of said second SIS version corresponds to the analyte amount at the upper end of the established clinical reference range for the analyte;
- and
- wherein said first and said second SIS versions differ from the analyte and from one another in mass and, said first and said second internal standards and said analyte have identical chemical structures, wherein said known amount of said SIS versions of said analyte correspond to the analyte amount at a pre-determined test evaluation threshold, and wherein said test evaluation threshold is a clinical decision threshold derived from a clinical study establishing test sensitivity and specificity at said threshold.
1 more element
Dependencies are inferred from the claim text.